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Abstract
Age-related increases in monoamine oxidase B (MAO-B) may contribute to neurodegeneration associated with Parkinson’s
disease (PD). The MAO-B inhibitor deprenyl, a long-standing antiparkinsonian therapy, is currently used clinically in concert
with the dopamine precursor L-DOPA. Clinical studies suggesting that deprenyl treatment alone is not protective against PD
associated mortality were targeted to symptomatic patients. However, dopamine loss is at least 60% by the time PD is
symptomatically detectable, therefore lack of effect of MAO-B inhibition in these patients does not negate a role for MAO-B
in pre-symptomatic dopaminergic loss. In order to directly evaluate the role of age-related elevations in astroglial MAO-B in
the early initiation or progression of PD, we created genetically engineered transgenic mice in which MAO-B levels could be
specifically induced within astroglia in adult animals. Elevated astrocytic MAO-B mimicking age related increase resulted in
specific, selective and progressive loss of dopaminergic neurons in the substantia nigra (SN), the same subset of neurons
primarily impacted in the human condition. This was accompanied by other PD-related alterations including selective
decreases in mitochondrial complex I activity and increased mitochondrial oxidative stress. Along with a global astrogliosis,
we observed local microglial activation within the SN. These pathologies correlated with decreased locomotor activity.
Importantly, these events occurred even in the absence of the PD-inducing neurotoxin MPTP. Our data demonstrates that
elevation of murine astrocytic MAO-B by itself can induce several phenotypes of PD, signifying that MAO-B could be directly
involved in multiple aspects of disease neuropathology. Mechanistically this may involve increases in membrane permeant
H2O2 which can oxidize dopamine within dopaminergic neurons to dopaminochrome which, via interaction with
mitochondrial complex I, can result in increased mitochondrial superoxide. Our inducible astrocytic MAO-B transgenic
provides a novel model for exploring pathways involved in initiation and progression of several key features associated with
PD pathology and for therapeutic drug testing.
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Introduction
Monoamine oxidase B (MAO-B) is found in the brain primarily
in non-neuronal cells such as astrocytes and radial glia [1–3]. Its
levels are known to increase with age and in association with
neurodegenerative disease in both humans and mice [4–7].
Substrate oxidation by the enzyme is accompanied stoichiomet-
rically by the reduction of oxygen to H2O2 [8,9]. It has been
postulated that age-related increases in MAO-B activity may
contribute to cellular degeneration in the brain due to corre-
sponding increases in the production of this reactive oxygen
species (ROS)[10]. Although MAO-B is expressed primarily in
astrocytes and not directly within dopaminergic cells, H2O2 has a
high membrane permeability and therefore it can induce toxic
effects not only within the cell of origin, but also in neighboring
cells [11]. The area of the brain preferentially impacted in
Parkinson’s disease (PD), the substantia nigra (SN), contains high
levels of MAO-B positive astrocytes which are themselves
somewhat protected against the effects of H2O2 due to the fact
that they contain high levels of both GSH and glutathione
peroxidase which act in concert to detoxify H2O2 within cells [11–
15]. Neurons, which contain significantly lower levels of these
protective components, are particularly vulnerable to this mild
oxidizing agent [16–18]. This suggests that H2O2 produced within
astrocytes by MAO-B may be either broken down to H2O within
these cells or may diffuse to vulnerable nearby cells such as
dopaminergic neurons [19]. MAO-B activity levels have been
found to be doubled in the SN in Parkinson’s disease, and to
correlate with the percentage of dopaminergic SN cell loss [20].
This suggests that increases in MAO-B levels could play a role in
subsequent dopaminergic cell death.
MAO-B-catalyzed ROS production has been suggested to
contribute to an age-related increase in mitochondrial damage
particularly in the SN [21]. Previous in vitro studies from our
laboratory demonstrated that increases in H2O2 generation as a
consequence of inducible increases in MAO-B levels results in
selective inhibition of mitochondrial complex I activity which
impacted on mitochondrial function within cultured dopaminergic
cells [22]. Selective reductions in complex I activity are associated
with PD and selective inhibition of complex I via systemic
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tetrahydropyridine (MPTP) results in patterns of morphological
damage in rodents similar to that observed in the human
Parkinsonian midbrain[23,24]. MAO-B is responsible for conver-
sion of MPTP to MPP
+ within astrocytes from where MPP
+ can
diffuse extracellularly. From there, it can be selectively transported
into dopaminergic neurons via the dopamine transporter and elicit
inhibitory effects on mitochondrial complex I activity [25].
There are numerous reports demonstrating the neuroprotective
effects of the MAO-B inhibitors deprenyl or selegiline in
Parkinsonian animal models although in many cases neuropro-
tection has been attributed to either antioxidant or antiapoptotic
properties of the parent compounds or their metabolites [26–28].
Several multi-center studies including DATATOP, addressing the
efficacy of selegiline administration in Parkinson’s disease (PD)
patients have concluded that selegiline both delayed and reduced
the requirement of L-DOPA supplementation in early stages of
symptomatic PD [29–31] but had no effect on the mortality rate
[32]. Although deprenyl was found to be ineffective in slowing or
halting the ultimate mortality in clinical PD it was given to patients
only after symptoms were present which is known to coincide with
the presence of an already extensive (,60%) midbrain dopami-
nergic cell loss [33]. These studies suggestthat inhibition of MAO-B
activity at this advanced stage in the disease is ineffective but this
does not necessarily prove that MAO-B elevation is not a factor in
initial neuropathology associated with the disorder and MAO-B
inhibitors if given pre-symptomatically might not be protective. In
order to test the hypothesis that elevations in MAO-B can directly
contribute to pathologies observed in PD and to better understand
the possible mechanisms underlying its effects on these parameters,
we created genetically engineered mouse lines in which MAO-B
levels can be inducibly increased specifically within astrocytes in
adult animals. This allowed us to bypass any impact of its increased
expression during the developmental time period. We report here
that astrocytic elevation of MAO-B in adult mice recapitulates many
of the pathological hallmarks associated with human PD and that
these effects can be prevented by treatment with the selective MAO-
B inhibitor deprenyl or the antioxidant EUK189.
Results
Creation of transgenic mouse lines in which astrocytic
MAO-B activity can be inducibly increased in adult
animals
Double transgenic mouse lines were generated in our laboratory
that constitutively express a reverse tetracycline responsive
transactivator (rtTa) protein specifically within astrocytes via a
glial fibrillary acidic protein promoter (pGFAP). Upon addition of
the tetracycline derivative doxycycline (dox), rtTa binds to a
tetracycline responsive bidirectional promoter (TET) and induces
simultaneous expression of both wildtype human MAO-B cDNA
(GenBank accession number NM 000898) and the marker protein
bacterial beta-galactosidase (lacZ) (Figure 1A). Expression of the
two co-transgenes was induced in our studies via inclusion of dox
in the normal mouse chow, and visualized by RT-PCR (Figure 1B).
Whole brain extracts from induced animals with the highest levels
of expression exhibited an approximate 2.5-fold increase in MAO-
B and lacZ activities versus uninduced controls (Figure 1C);
increased MAO-B activity was completely inhibited by deprenyl
treatment (data not shown). This high-expressing line was used for
all subsequent studies. Immunohistochemistry using antibodies
specific to MAO-B demonstrated that the human MAO-B was
exclusively expressed within (GFAP) astroglia throughout the brain
and only following dox treatment (Figure 1D).
Elevation in astrocytic MAO-B results in increased
conversion of MPTP to MPP
+ and significant increases in
toxin-induced dopaminergic SN cell loss
To validate that our transgenic model expresses functionally
active MAO-B, we assessed its vulnerability to acute systemic
MPTP administration. Since conversion of MPTP to MPP
+ is
catalyzed by MAO-B, we predicted that elevation in functional
astrocytic MAO-B should result in increased striatal MPP
+ levels
and exacerbation of selective MPTP-induced dopaminergic SN
neurodegeneration. Induced and uninduced transgenic mice and
wildtype C57Bl6 littermates were treated with 30 mg/kg MPTP
and striatal MPP
+ levels measured via HPLC (Table 1). At
90 minutes post MPTP injection, striatal MPP
+ levels were 1.5-
1.8-fold that observed in either uninduced transgenic or wildtype
controls. This increase in striatal MPP
+ was accompanied by a
significant decrease instriatal dopamine levelsand dopaminergicSN
cellnumbersininduced transgenics compared to controlsseven days
following MPTP treatment (Figures 1E & 1F). MAO-B elevation
alone was found to result in ,60% reduction in striatal dopamine
levels (Figure 1E) which was exacerbated further by MPTP.
Elevations in astrocytic MAO-B in our transgenics resulted in
exacerbation of MPTP-induced neurotoxicity suggesting that
astrocytic MAO-B increases had the expected functional effect.
Astrocytic MAOB elevation in mesencephalic cultures isolated
from inducible MAO-B lines was found to result in dopaminergic
neurodegeneration. Mesencephalic cultures were prepared from
day-14 embryos from transgenic mice and wildtype littermates.
Mixed neuronal/glial mesencephalic cultures were grown on
coated plates for 3 days and transgenic MAO-B activity induced in
a portion of the transgenic cultures by addition of 40 mg/ml dox.
Dox was added to wildtype cultures as a negative control. Twelve
hours following dox addition, immunocytochemistry performed on
dox-induced transgenic cultures revealed a significant loss in the
number of tyrosine hydroxylase positive (TH
+) cells compared to
controls even in the absence of toxin addition that was attenuated
by deprenyl co-treatment (Figure 2A). To verify that loss of TH
immunostaining represents actual preferential loss of dopaminer-
gic cells, we counted the number of cells within the cultures which
take up the fluorescent dopamine analogue ASP
+ (4-(4-(dimethy-
lamino)styryl)-N-methylpyridinium iodide, Molecular Probes) as a
measure of cells with functional dopamine transporter activity. We
found a similar percentage loss of ASP
+ cells (,80%, 44622
versus 244668 uninduced per field). This demonstrates that the
loss in TH
+ cell numbers is not simply a consequence of selective
loss of this particular marker. In addition to increased dopami-
nergic cell loss, the remaining dopaminergic neurons were
observed to undergo significant loss of their neurite processes
which became stunted and shrunken in size. Deprenyl co-
treatment attenuated not only the extensive dopaminergic cell
loss observed following induction of MAO-B within cultured
astrocytes but also the observed morphological dopaminergic
neurite alterations (Figure 2B).
Elevations of astrocytic MAO-B in vivo results in selective
dopaminergic SN cell loss
To assess the impact of astrocytic MAO-B elevation on its own
in vivo on the nigrostriatal system, stereological dopaminergic cell
counts were performed on dox-fed transgenic mice versus controls.
A two week induction period in 2–3 month old transgenics
resulted in an approximate 40% loss in dopaminergic SN cell
numbers compared to either untreated transgenics or wildtype
littermates; this loss was prevented by deprenyl co-treatment
(Figure 3A). Moreover, removal of dox from the animal feed after
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TH
+ counts to normal levels. Astrocytic MAO-B elevation in older
(14 mo.) transgenics resulted in an even more pronounced
dopaminergic SN cell loss (,50%) than that observed in the
younger animals. In contrast, total neuronal numbers in the SN as
assessed by NeuN staining did not differ between dox-treated
transgenics versus untreated controls nor were neuronal cell
numbers in the striatum or cortex impacted by astrocytic MAO-B
elevation (Figures 3B), even though it occurred throughout the
brain and resulted in a general and widespread astrogliosis as
evidenced by GFAP immunocytochemistry in these same brain
regions (Figures 3C, D). GABAergic SN cell counts also revealed
no difference in dox-induced versus non-induced animals further
suggesting that the observed dopaminergic cell loss in this brain
region was selective (data not shown). GFAP immunostaining
revealed profuse branching as normally observed following
astroglial activation and increased astroglial brain numbers
following dox treatment which were inhibited by deprenyl. Levels
of S100-b, a marker for activated astrocytes, were also increased in
transgenic astroglia following dox induction (Figure 3E).
We performed silver staining to verify that selective loss of TH
+
immunostained cells in the SN following dox induction coincided
with increased neurodegeneration in this brain region (Figure 3F).
This data along with the dox removal results suggests that the
decrease in TH
+ SN cells is not merely due to a reversible selective
loss of the TH
+ marker but constitutes an irreversible dopami-
nergic SN neurodegeneration.
Astrocytic MAO-B elevations result in increased
mitochondrial oxidative stress in dopaminergic SN
neurons
Based on our data, global increases in astrocytic MAO-B
appeared to result in a preferential neurodegeneration of dopami-
nergic neurons suggesting that dopamine itself may be involved in
the neurodegenerative process. Recent work in isolated brain
mitochondria [34] demonstrated that dopamine oxidized to
dopaminochrome (DACHR) can remove electrons from the auto-
oxidizable site in mitochondrial complex I forming dopamino-
chrome radical. Dopaminochrome radical can in turn react with O2
present in the mitochondria converting it to O2
2 in concert with re-
reduction of the dopaminergic radical, setting up a redox cycling
event. This would be manifest as an increase in mitochondrial O2
2
levels and ROS-induced complex I inhibition within the dopami-
nergic neurons which could result in their selective demise. We
hypothesized that membrane-permeant H2O2 produced by in-
creased MAO-B activity within astrocytes could interact with
intercellular dopamine and produce selective degenerative effects
on dopaminergic neurons via a similar mechanism. To first test for
the ability of astrocytes with elevated MAO-B activity to produce
increased levels of extracellular ROS, we measured H2O2 generated
in the culture medium in mesencephalic cultures isolated from our
inducible MAO-B transgenics following dox induction. H2O2 levels
released into the media in dox-induced cultures were significantly
higher than those produced from untreated cultures (Figure 4). Co-
treatment with deprenyl prevented the increase in extracellular
H2O2 as did treatment with the antioxidant superoxide dismutase-
catalase mimetic compound EUK-189. Co-treatment with apoc-
ynin, an NADPH oxidase inhibitor, resulted in a partial reduction in
the H2O2 levels indicating that microglial activation contributes to
the ROS increase although it is not clear whether this is directly due
to astroglial activation or a secondary effect of dopaminergic cell
death in the cultures. Iba1
+ cells (a 17 kDa calcium binding protein
expressed in microglia) were found to constitute 3% of the total cell
r
Figure 1. Characterization of transgenic mice that inducibly express human MAO-B specifically within astrocytes. A. Schematic of
transgenic constructs utilized to create transgenic mice with inducible elevation of human MAO-B (h-MAO-B) expression
specifically within astrocytes via the bacterial tetracycline regulatory system. A bacterial reverse tetracycline response gene (rtetR) was
expressed constitutively via a mouse glial fibrillary acidic protein promoter (pGFAP). The resulting gene product, rtTA, a tet-responsive transactivator
protein, is activated only in the presence of doxycycline (dox) and is able to bind to a tetracycline operator (TET) sequence in the promoter of a
second transgene, resulting in induction of expression of both h-MAO-B and bacterial beta-galactosidase (lac Z) from the bidirectional promoter. B.
Human MAO-B cDNA transgene is expressed in the brains of transgenic mice following dox induction. Inducible transgene mRNA
expression (a 448 bp amplicon) was visualized by RT-PCR from RNA isolated from whole brains of uninduced (U), dox-induced (I) transgenic mice and
wild type littermates (W). C. Enzymatic activities of h-MAO-B and lacZ transgenes in whole brain lysates from uninduced (ND) and dox-
induced (D) transgenic animals. n=3 animals per condition run in triplicate; * p,0.01. Data is presented as percent ND control. ND lacZ activity
was calculated to be 11.960.54 nmoles ONPG converted/mg protein/hour and wild type C57BL6 lacZ activity (not shown) to be 11.360.13 nmoles
ONPG converted/mg protein/hour respectively. Brain MAO-B activity in tissue isolated from the uninduced transgenic (ND) was calculated to be
14.660.9 nmoles b-PEA converted/mg protein/hour and in tissues from wild type C57BL6 mice (not shown) to be 14.260.23 nmoles b-PEA
converted/mg protein/hour. D. Dox-inducible expression of human MAO-B (h-MAO-B) and lacZ is localized within GFAP
+ astrocytes.
GFAP immunostaining is shown in green, h-MAO-B is red, and merged in yellow in uninduced (No DOX) and dox-induced (DOX) animals. Scale bar
applies to all images. E. Loss in striatal dopamine (ST DA) content is exacerbated in dox-induced transgenics following a single MPTP
injection of 30 mg/kg body weight. Striatal dopamine was estimated from wild type (W), uninduced transgenics (ND), induced transgenics (D),
and dox-induced transgenics co-treated with deprenyl (Ddep). Grey bars without MPTP, black bars after a single injection of 30 mg/kg MPTP. Data is
expressed as ng dopamine/mg striatal protein. * p,0.01 D vs. ND, **=p,0.01 Ddep vs. ND. F. Loss in dopaminergic tyrosine-hydroxylase-
positive (TH
+) neurons in the substantia nigra (SN) after a single injection of MPTP (30 mg/kg) is exacerbated in dox-induced mice.
Uninduced transgenic mice (ND), induced transgenics (Dox), and induced transgenics co-treated with 10mg/kg deprenyl (Doxdep). Data is presented
as percent of non-MPTP treated ND controls where SN TH
+ cell numbers are estimated at 13,3186475 TH
+ neurons in untreated ND mice (WT values,
not shown, were 13,6996325). n=3 animals per condition run in triplicate; * p,0.05.
doi:10.1371/journal.pone.0001616.g001
Table 1. Striatal MPP
+ levels.
MPP
+ levels
MPP
+ (ng/mg protein)
Dox 18263.4
No dox 11862.3
WT 10063.5
MPP
+ levels were measured in striatal tissues collected from wildtype (WT),
uninduced (No dox) and dox-induced (Dox) transgenic mice 90 min post-MPTP
injection (30 mg/kg) via HPLC with electrochemical detection. MPP
+ was
extracted from tissues homogenized in the presence of 0.4N perchloric acid and
measured against a known standard. Values are presented as ng MPP
+/mg
protein , n=3 per treatment condition.
doi:10.1371/journal.pone.0001616.t001
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dox induction (data not shown).
Dopaminergic neurons constitute only a minor portion (, 5%)
of cells making up the SN (unpublished observations). In contrast
to the SN, the striatum (ST) is larger, easier to dissect out, and at
least 10–15% of the striatal nerve terminals originate from SN
dopaminergic neurons [35–37]. In order to achieve meaningful
data as to the impact of astrocytic MAO-B elevation on H2O2
levels and mitochondrial function selectively within dopaminergic
nigrostriatal neurons, we chose to enrich for striatal dopaminergic
Figure 2. Inducible elevation of astrocytic MAO-B levels in mesencephalic cultures isolated from transgenic mice results in TH
+ cell
loss which is prevented by co-treatment with deprenyl. A. TH
+ cell counts in uninduced mesencephalic cultures isolated from either
wildtype littermates (WT), uninduced transgenics (ND) or transgenic cultures induced with 40 mg/ml doxycycline for 24 hrs in the
absence (D) or presence of 10
-6M deprenyl (Ddep). Counts are expressed as % WT values which were estimated to be 300615 TH
+ neurons.
Cell counts were performed in a minimum of three different wells and 4 separate fields in each well. *=p,0.01 compared to ND; **p.0.01 compared
to Dox. B. Representative micrographs of the TH
+ cells obtained by TH
+ immunofluorescence in uninduced (No Dox), dox-induced
(Dox) and dox-induced mesencephalic cultures treated with deprenyl (Doxdep). Note the truncated processes and shrunken
dopaminergic cell morphology in the induced cultures versus uninduced and deprenyl-treated induced cultures.
doi:10.1371/journal.pone.0001616.g002
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DAT via a modified immunomagnetic bead approach (Fig. 5A,B).
Synaptosomes in the flow-through fractions were non-dopaminer-
gic (GABA
+) and therefore used as negative controls in our
subsequent biochemical analyses.
H2O2 levels were measured in isolated ST dopaminergic
synaptosomes following injection of DCF into the tail vein of
dox-induced versus uninduced and wildtype littermate controls as
modified from Andrews et al. [38]. H2O2 levels was found to be
elevated in isolated ST dopaminergic synaptosomes following
increased astrocytic MAO-B elevation; this was found to be
preventable by co-treatment of animals with either deprenyl or
EUK-189 (Fig. 5C). Catalase treatment of the dopaminergic
synaptosomes from the induced animals reduced the fluorescence
to below uninduced levels indicating that the DCF fluorescence is
due to H2O2. In conjunction with elevations in H2O2 within
nerve terminals originating from dopaminergic SN neurons, we
found an elevation in striatal DACHR. DACHR is a stable
derivative of dopamine quinone, the major species produced by
dopamine oxidation [39] (Figure 5D). Along with increases in
DACHR levels, we found a preferential reduction in rotenone-
inhibitable complex I (CI) activity in the ST dopaminergic versus
non-dopaminergic synaptosomes (Figure 5E). In contrast, no
change in complex IV activity was observed in either population
following dox-induction (Figure 5E). Loss of CI activity was
attenuated in dopaminergic synaptosomes isolated from dox-
induced animals that had been co-treated with deprenyl or
EUK-189.
To assess whether increased dopaminergic H2O2 and DACHR
levels following astrocytic MAO-B elevation in vivo resulted in
corresponding increases in mitochondrial O2
2 levels within
dopaminergic cells as previously demonstrated in vitro by
Zoccarato and colleagues [34], animals were administered the
superoxide indicator mitosox red via tail vein injection[38]. Dox-
induced transgenics displayed elevated presence of mitosox red
staining within mitochondria in both TH
+ fibers in the striatum
and in TH
+ neurons within the SN versus uninduced controls
(Figure 6, Table 2). Increases in mitosox red fluorescence within
the dopaminergic SN neurons were prevented by co-treatment
with either deprenyl or EUK189 (Figure 6, Table 2). Significantly,
dopaminergic SN cell loss was found to be attenuated in the
presence of co-treatment with not only deprenyl, but also EUK189
suggesting that oxidative stress is an important component of
dopaminergic demise (Figure 3A).
r
Figure 3. Inducible elevation in astrocytic MAO-B results in selective, age-related SN dopaminergic neurodegeneration and global
astrocyte activation even in the absence of neurotoxin. A. TH
+ SN cell counts from uninduced transgenics (no dox) versus induced
transgenics at 3-4 months (dox) , following dox removal (dox rem) at 14 months of age (dox 14 mo), and induced co-treated with
deprenyl at 10-30 mg/kg (dox dep 10-30), the anti-inflammatory agent minocycline at 10 mg/kg (dox mino) or the anti-oxidant
Euk189 at 10 mg/kg in young animals. Data is expressed as total number of SN TH
+ cells numbers per animal; *p,0.01 compared to ND, ** p,
0.05 compared to Dox, and *** p, 0.05 compared to dox. B. Neuronal (NeuN
+) counts from uninduced (No Dox, filled bars) versus dox-
induced transgenics (Dox, open bars) performed in equivalent nigral (SN), cortical (CT), and striatal (ST) tissue sections. Values
represent average cell numbers per field in three separate fields per section, three sections per animal. N=5 animals per group. C. Representative
micrographs demonstrating cortical astrocytic activation in dox-induced (Dox) versus uninduced (ND) animals and dox-induced
animals co-treated with deprenyl (Ddep). Astrocytes from induced transgenics displayed enhanced GFAP staining and increased branching
indicative of astrocyte activation (higher magnification in lower middle panel); deprenyl treatment resulted in reduced branching similar to that
observed in uninduced controls (higher magnification in lower right-hand panel). D. Astrocytic (GFAP
+) counts from uninduced (No DOX,
open bars) versus dox-induced transgenics (DOX, light grey bars) and mice dox-induced in the presence of deprenyl co-treatment
(D DEP, dark grey bars) performed in equivalent striatal (ST), nigral (SN), and cortical (CT) tissue sections. Values represent average cell
numbers per field at 406magnification in three separate fields per section, three sections per animal. N=5 animals per group; *p.0.05, ** p,0.1. E.
Representative micrograph demonstrating increased expression of the astrocytic activation marker S-100b (blue) in GFAP
+ cells in
the transgenic cortex following dox induction. GFAP-labeled astrocytes (red) in induced animals display increased S-100b staining (pink) versus
uninduced. F. Neurodegeneration of TH
+ cells as assessed by silver staining. SN sections from uninduced (No Dox) and induced (Dox)
animals were processed for TH
+ immunoreactivity visualized by alkaline peroxidase (blue) and further processed for silver staining. A black punctate
staining was observed in and around dying TH
+ neurons (arrows) in Dox but not No Dox fields.
doi:10.1371/journal.pone.0001616.g003
Figure 4. Elevation in astrocytic MAO-B results in increased extracellular hydrogen peroxide (H2O2). Extracellular H2O2 concentrations
were measured in media isolated from uninduced (ND) versus dox-induced (Dox) mesencephalic cultures in the absence and presence of 10 mM
deprenyl (Dox Dep), 30 mM EUK189 (Dox Euk) or 500 nM apocynin (Dox Apo) using the Amplex Red assay. H2O2 concentrations were quantified
against a standard H2O2 curve. Measurements were made on three separate media aliquots harvested prior to immunostaining of cultures; *p,0.01
compared to ND, ** p,0.05 compared to ND.
doi:10.1371/journal.pone.0001616.g004
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PLoS ONE | www.plosone.org 7 February 2008 | Volume 3 | Issue 2 | e1616Figure 5. Effects of elevations of astrocytic MAO-B on H2O2 and dopaminochrome (DAChr) levels, and mitochondrial complex I
versus IV activities in isolated ST dopaminergic versus non-dopaminergic synaptosomes. A. Schematic of novel immunomagnetic
technique utilized to for isolate ST dopaminergic versus non-dopaminergic synaptosomes. Synaptosomes were prepared from freshly
dissected striata and the dopaminergic population rapidly isolated via immunoprecipitation with anti-DAT antibody following by separation by a
magnetic particle-conjugated secondary antibody running through a strong magnetic column. Elution of the DA synaptosomes was obtained via
removal of the magnetic field. Flow-through contains striatal non-dopaminergic synaptosomes used as negative controls in subsequent biochemical
experiments. B. Densitometric quantitation of western blot analyses of fractions from immunomagnetic isolation of ST
Elevated MAO-B & PD Pathology
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local microglial activation in the SN
Data from our mitosox red studies not only suggested that SN
dopaminergic neurons display an increase in oxidative stress
following astrocytic MAO-B elevation, but also in the activated
local SN microglial cells (Fig. 7A). This is likely a secondary effect
subsequent to dopaminergic SN neurodegeneration triggering
local microgliosis. Degeneration of SN dopaminergic neurons in
PD has been observed to be accompanied by local microglial
activation [40]. It has also been noted post-mortem in both
humans and primates exposed to MPTP [41,42]. It is detected in
the chronic mouse rotenone model prior to appearance of the
r
synaptosomes probed with TH, GABA or SNAP-25 antibodies. Levels of Dopaminergic TH (grey bars) versus Non-dopaminergic GABA (white
bars) synaptosomes were assessed using SNAP-25, a general synaptic protein, as a loading control. Control (C), unbound fraction (U), flow-through
(FT), wash (W) and eluate (E). Representative blots are shown in the lower panel. C. Elevation in astrocytic MAO-B results in increased H2O2
within dopaminergic ST synaptosomes. H2O2 levels were estimated 3 hrs following tail vein injection of DCFDA into either wildtype littermates
(WT), uninduced (ND) or dox-induced (Dox) transgenics, or induced transgenic animals co-treated with either deprenyl (D DEP), EUK189 (D EUK) or
1 mg/ml catalase (Dox Cat). DCF fluorescence was examined at an excitation wavelength of 488 nm and emission at 512 nm. Data is reported
normalized to microgram synaptosomal protein. N=3; *p,0.005 versus ND, **=p,0.01 versus Dox. D. Elevation in astrocytic MAO-B results in
increased ST DAChr levels. DAChr levels were estimated in ST samples from uninduced (ND) versus dox-induced (Dox) transgenic mice via HPLC.
Values are presented as picomoles DAChr/mg protein.* p,0.02, n=3. E. Elevation in astrocytic MAO-B results in decreased complex I but
not complex IV activity in ST dopaminergic synaptosomes. Complex I and complex IV activities were measured in isolated ST dopaminergic
versus non-dopaminergic synaptosomes from uninduced (ND), dox-induced (Dox) and induced transgenic animals co-treated with either deprenyl
(Dep) or EUK-189 (EUK). N=3–5 animals per group and a total of 3 separate experiments, values are expressed as mean6SD; * p,0.01 compared to
ND, ** p.0.05 compared to ND. CI activity was calculated to be 4.0 versus 3.3 mM NADH/min/mg protein in ND striatal dopaminergic and non-
dopaminergic synaptosomes, respectively. CIV activity was calculated to be 139 versus 109 mM ferrocytochrome c/minute/mg protein in ND striatal
dopaminergic and non-dopaminergic synaptosomes, respectively. Activities of WT DA striatal synaptosomes was calculated to be 4.4 mM NADH/min/
mg protein (CI) and 130 mM ferrocytochrome c/minute/mg protein (CIV); dox feeding of the WT animals did not alter the activities. Note: addition of
doxycycline has been reported to interfere with mitochondrial protein translation including CI thereby affecting enzyme activity [62], however in
addition to lack of effect on CI activity in WT animals +/2 dox, we also find no change in CI subunit protein levels in WT mice as a consequence of dox
treatment as assessed via immunoprecipitation/gel electrophoretic analyses (data not shown).
doi:10.1371/journal.pone.0001616.g005
Figure 6. Elevation in astrocytic MAO-B results in increased mitochondrial superoxide levels within dopaminergic SN
mitochondria. Representative confocal micrographs illustrating increased merged (yellow) mitosox red fluorescence (red) in the SN and striatum
of dopaminergic neurons following tail vein injection, fixation and TH immunochemistry (green) in uninduced (No Dox) versus induced transgenic
mice (Dox) which is prevented in the presence of co-deprenyl (DEP) or EUK-189 (EUK) treatment. Nuclei are visualized via DAPI staining (blue).
doi:10.1371/journal.pone.0001616.g006
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neurodegeneration in the spontaneous weaver mouse mutant [44].
We performed immunochemistry to evaluate microglial activation
in our induced MAO-B transgenics via Iba1 immunostaining [45].
Prior to activation, microglia normally exhibit a highly ramified
morphology. In response to an activating signal, microglia begin to
withdraw their ramified branches and to extend new protrusions.
Next they begin migration through the tissue, engulfing cells [46].
Astrocytic MAO-B expression was found to lead to local microglial
activation in both the SN and the striatum (Figure 7 B–D) but not
the cortex (supplement Figure S1). Unactivated ramified microglia
were found in the uninduced nigrostriata and cortex; activated
microglia with reduced branching in locomotory stages were only
present within the SN and striatum of induced MAOB transgenics.
In some cases, the microglia were in a high motile state with
minimal processes or were in close contact with TH
+ neurons,
possibly in the phagocytic stage (Figure 7C). Microglial activation
was prevented by treatment with deprenyl (Figure 7B). Co-
treatment of animals with an inhibitor of microglial activation,
minocycline, prevented dopaminergic SN cell death suggesting
that microglial activation plays a major role in dopaminergic
neurodegeneration in this model (Figure 3A).
Increases in astrocytic MAO-B activity results in
decreased locomotor movement
Finally, astrocytic increases in MAO-B in our model were found
to correlate with a significant inhibition of locomotor function.
Open field analysis of dox-treated mice revealed a significant
difference in locomotor behavior in induced versus uninduced
transgenics (Figure 8A, B). After treatment with dox alone for two
weeks, induced mice displayed a ,32–35% decrease in locomotor
activity in comparison to uninduced littermates. In contrast,
deprenyl-treated induced mice were completely unaffected.
Discussion
Increased brain MAO-B levels have been hypothesized to play a
role in neuropathies associated with PD [47–51] however direct
proof of a causative role has been thus far lacking. In this study, we
demonstrate that elevations in astrocytic MAO-B levels results in a
relatively selective loss of dopaminergic SN neurons and the
severity of this loss appears to be age-dependent. It is not clear why
there was not a more dramatic increase in SN DA cell loss with
age in the MAO-B transgenics. Normally, cell loss coincides with
an age-related increase in MAO-B enzyme activity. Our results
suggest that perhaps the elevation of MAO-B to aging levels in the
young animals was sufficient on its own to produce significant cell
loss and that the additional stress of an aging brain contributed
marginally (yet significantly) to this effect. Observed cell loss was
accompanied by increased mitochondrial oxidative stress and
selective decreases in mitochondrial complex I activity in these
cells along with local microglial activation all of which we assume
contribute to subsequent cell death. These pathological alterations
were found to correlate with a significant decrease in locomotory
behavior. Our data, taken in total, demonstrates that elevations in
levels of astrocytic MAO-B activity results in several of key
pathological hallmarks of Parkinson’s disease.
ROS produced by MAO-B-expressing astrocytes can be
released into the extracellular environment and, due to its high
membrane permeability, diffuse into neighboring cells. Within
dopaminergic neurons, it can oxidize dopamine to DACHR which
can interact with electrons at the auto-oxidizable site of
mitochondrial complex I at a higher affinity than oxygen itself
producing DACR radical. Electrons can then be transferred from
DACR radical to oxygen resulting in re-reduction of DACR to
DACHR and production of superoxide as part of an ongoing
redox cycling event. These events are shown schematically in
Figure 9. We have demonstrated in this current study that
increased astrocytic MAO-B results in elevations in extracellular
ROS levels and increased intracellular H2O2 within the terminals
of SN dopaminergic neurons accompanied by increased dopamine
oxidation to DACHR, selective mitochondrial complex I inhibi-
tion and elevations in mitochondrial superoxide levels. These
events are prevented by either co-treatment with the MAO-B
inhibitor deprenyl or the antioxidant compound EUK189 which
also prevented subsequent dopaminergic SN cell loss.
Another prominent feature noted in our model was local
microglial activation within the nigrostriatum. Dramatic local
proliferation of microglial cells has been reported in the post-
mortem PD brain as well as in various animal models of the
disease [40,43,44,52–54].Local microglial activation was found to
be associated in our model with degenerating TH
+ cells in both the
SN and the striatum. It may be a secondary reaction to initiation
of dopaminergic neurodegeneration. Significantly, dopaminergic
SN cell loss is substantially attenuated by co-treatment of animals
with the microglial activation inhibitor minocycline suggesting that
microglial activation plays a significant role in dopaminergic
demise associated with this model.
Taking in total, our data demonstrates a linkage between several
separate pathological events associated with Parkinson’s disease
that have not necessarily been considered to be mechanistically
connected including mitochondrial dysfunction, and microglial
activation. This suggests that MAO-B may be a common initiator
for these events and provides a novel model for exploring the
mechanisms by which these events can occur in the context of the
human condition.
Materials and Methods
Generation and analysis of transgenics with inducible
astrocyte-specific elevation of MAO-B levels
Human MAO-B cDNA was cloned into pBIG (Clontech) at the
PstI and SalI sites, placing the gene under transcriptional control
of the bidirectional Tet-inducible promoter. A second construct
was prepared which contained the 3.7 kb HinDIII-BamHI
fragment of the mouse GFAP promoter cloned in EcoRI blunt
ended pTetOn vector, driving expression of the Tet-responsive
reverse transactivator rtTA. Transgenic C57Bl6 mice inducibly
expressing human MAO-B selectively within astrocytes were
Table 2. Superoxide in the SN dopaminergic neurons.
Mean pixel intensity Total pixel fluorescence
per cell per cell
ND 10.862.0 101,983617,686
D 24.263.6 223,526628,225
DD 10.262.1 91,937619,107
DEUK 15.464.0 126,757623,798
Confocal quantitation of relative mitosox-red fluorescence intensity in SN DA
neurons in untreated (ND) or dox-treated (D) transgenic mice in the absence or
presence of deprenyl (DD) or EUK-189 (DEUK). Confocal images from
immunofluorescent sections of brains were obtained following various
treatment regimes and subjected to intensity measurements using the IMARIS
software suite (Bitplane AG, Zurich, Switzerland) on selected cells from multiple
sections from each treatment. Data is presented both as mean pixel intensity
and total red fluorescent pixels (mitosox red) per cell.
doi:10.1371/journal.pone.0001616.t002
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following dox treatment reveals increased mitochondrial superoxide levels within these cells. Microglia were immunostained with Iba1
(green) antibody in sections of brain fixed 3 hrs following tail injection of mitosox red. Confocal detail shows mitochondrial mitosox red fluorescence
within an activated microglial cell body following dox induction. B. Microglial activation occurs following dox induction within the SN.
Microglial activation as assessed by Iba1 immunochemistry (black, DAB-nickel staining) in SN sections from uninduced (No Dox), induced (Dox), and
dox-induced co-deprenyl-treated transgenics (Ddep). Dopaminergic (TH
+) neurons are labeled in brown (DAB). Note that few activated microglia are
visible in No Dox and Ddep treated mice versus in the Dox panel where several stages of microglial activation (resting, activated, withdrawing, and
motile stages) can be visualized. Scale bar equals 50 mM unless indicated otherwise. C. Higher magnification of representative SN Iba1
immunochemistry demonstrating stages of microglial activation (activated, withdrawing, and motile stages are indicated by cartoons).
Cortical microglia were found to be in a ramified or resting stage in all the conditions (supplementary figure S1). D. Representative Iba1
immunochemistry in ST sections demonstrating increased microglial activation following dox induction. Shown are ST sections from
uninduced (No Dox) versus dox-induced (Dox) or dox-induced, co-deprenyl treated (Ddep) transgenics. Note the presence of numerous retracted
processes in the microglia in the Dox panel versus presence of ramified microglia in the No Dox and Ddep panels.
doi:10.1371/journal.pone.0001616.g007
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pronuclei of a fertilized egg prior to implantation into a
pseudopregnant female. Subsequent founder mice were crossed
with wildtype C57Bl6 and resulting litters genotyped by PCR
using the primers 59ACTGAACCCAAAGGCACAC39 and
59AACATGACAATGAAGGAGCTAC39 for MAO-B, and
59GCCTTTACCCATTACC39 and 59CCCGCTTATTTTT-
AATGC39 for rTta. Littermates positive for both transgenes were
mated to achieve homogeneous lines. Astroglial-specific transgene
expression was induced by feeding animals doxycycline at
3000 ppm provided in pre-mixed Purina chow (Research Diets)
for a three week period. Assuming a 5 g diet per day for a 30 g
mouse, the dosage achieved was calculated to be equivalent to
0.5 g/kg/day. Total RNA was isolated from cortical brain tissue
of wildtype uninduced and uninduced transgenic mice using
Trizol (Invitrogen).according to manufacturer’s instructions.
cDNA was prepared using Superscript III reverse transcriptase
kit (Invitrogen) and oligo-(dT) primers from 2 mg of total RNA.
PCR was carried out with the forward and reverse primers
corresponding to human MAO-B cDNA as above using Taq
polymerase (Eppendorf). A 448bp amplicon indicates the induc-
tion of the h-MAO-B transcript. Positive transgene induction was
also confirmed based on MAO-B and betagalactosidase positive-
immunostaining within astrocytes of dox-induced transgenics
using antibodies specific to hMAO-B and betagalactosidase within
GFAP
+ cells. Betagalactosidase and MAO-B enzyme activities
were also performed in whole brain homogenates from induced
versus uninduced transgenic lines [2,55]. The line showing the
highest level of induction was used for all subsequent studies. Mice
were housed according to standard animal care protocols, fed ad
libitum, kept on a 12 hr light/dark cycle, and maintained in a
pathogen-free environment in the Buck Institute Vivarium.
Animals used for subsequent studies were either young adults
(2–6 months of age) or older animals (14 months of age) fed dox
on the regime described above. Co-treatment with other agents
involved intraperitoneal administrations of 10–30 mg/kg/day of
deprenyl, minocycline or EUK-189 for two weeks.
MPP
+ measurements, striatal dopamine content cell
counts and neurodegeneration in inducible astrocytic
MAO-B transgenics versus controls +/- MPTP
Striatal tissue was harvested from dox versus untreated animals
90 minutes following injection of 30 mg/kg MPTP intraperitone-
ally, immediately immersed in ice cold 0.1 M perchloric acid and
sonicated. MPP
+ was measured by HPLC as previously described
[56]. Dopamine levels were analyzed in striata dissected two weeks
of induction or 24 hrs following MPTP injection post induction by
HPLC followed by a 464 pulsed electrochemical detection
(Neurochemistry Core, Center for Molecular Neuroscience,
Vanderbilt University). Stereological cell counts were performed
on immunostained brain sections from brains harvested two weeks
after induction using either antibody against tyrosine hydroxylase
(TH, Chemicon, 1:500) followed by biotin-labeled secondary
antibody and development using DAB (Vector Laboratories). TH
+
cells were counted stereologically throughout the SNpc [56].
Counts for dox removal were performed on brains dissected after
removal of dox from the feed for a three week period. Sections
were cut at a 40 mm thickness, and every 4th section was counted
using a grid of 1006100 mm. Dissector size used was
35635612 mm. Neuronal numbers were assessed following
NeuN
+ (Chemicon, 1:100) or GABA
+ (Chemicon, 1:1000)
immunostaining and astrocytes via GFAP
+ (DAKO, 1:500) and
s100-b (DAKO, 1:200) immunostaining. Cells were counted in the
SN, striata, and cortex in three independent sections per condition
and ten fields per section. Neurodegeneration in the TH
+ cells was
visualized by silver staining (FD Neurotechnologies, Ellicott City,
MD) according to the manufacturer’s instructions using proprie-
tary compounds after immunostaining the sections with antibody
against tyrosine hydroxylase (TH, Chemicon, 1:500) visualized
with Vector Blue alkaline phosphatase (Vector labs). Dopamino-
chrome was measured from striatal samples by HPLC as per Ochs
et al [39].
Extracellular H2O2 levels and dopaminergic cell survival in
mesencephalic cultures
Primary mixed cultures were prepared from the midbrain of 14-
day-old mice embryos from MAO-B transgenics and WT controls.
Tissue was digested in Neurobasal medium containing 30 U/ml
papain and 20 mg/ml DNase at 37uC for 30 min and mechanically
triturated.Dissociatedcellswerecentrifugedat5006g,resuspended
in growth medium (Neurobasal medium supplemented with 10%
FBS, 2 mM glutamate, B25 supplement without antioxidants,
Figure 8. Elevation in astrocytic MAO-B results in loss of
ambulatory movement in MAO-B transgenics. Total ambulatory
velocity (A) and ambulatory distance (B) following two weeks of dox
administration. Data is presented as average ambulatory velocity
calculated over a 10 minute observation period and total ambulatory
distance is for that same time interval. N=5 mice per condition;
experiments were run in triplicate. * p,0.01 compared to ND, **
p.0.05 compared to ND. Values are given for untreated (ND), dox-
treated (Dox), and dox, deprenyl co-treated mice. Wildtype untreated
littermates had an ambulatory velocity of 2.3760.45 cm/s and a total
ambulatory distance moved of 10826101 cm.
doi:10.1371/journal.pone.0001616.g008
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[57]), and plated on poly-d-lysine-coated 8 well chamber slides (BD-
Biocoat) at a density of 10
5 cells per ml. Mixed cultures were grown
at 37uC for 3–5 days before induction with 40 mg/ml doxycycline
for 12 hours as per [22]. Cells were co-treated with 10 mMd e p r e n y l
or 500 nM apocynin. H2O2 in the medium was assayed by Amplex
Red per the manufacturer’s instructions. Dopaminergic and
microglial cell counts were performed following fixation of the
cultured cells for 15 min with 4% formaldehyde following by TH
+
(Chemicon) or Iba1
+(WAKO USA, Richmond, VA) immunostain-
ing or via uptake of ASP
+ (4-(4-(dimethylamino)styryl)-N-m e t h y l -
pyridinium iodide) (Invitrogen), a fluorescent analogue of dopamine.
10 mMA S P
+ was loaded on to the uninduced or induced cultures in
the presence of 20 mM of desipramine to inhibit the norepinephrine
transporter which would also take up the dye. ASP
+ fluorescence
(red) was visualized in the TH
+ cells after immunostaining with anti-
TH antibody and Alexa fluor 488 conjugated secondary antibody.
Averages of manual double blind TH
+ or fluorescent counts of three
wells of culture with the same treatment were collected; counts were
performed in triplicate.
Figure 9. A schematic representation of the events occurring upon the elevation of glial MAO-B. Increased astroglial levels of MAO-B
results in elevation of H2O2 levels; this can be prevented by deprenyl. Astroglia are themselves protected from H2O2 due to relatively high levels of
glutathione-gluathione peroxidase versus neurons. H2O2 can diffuse out of astroglia and into neighboring cells including local dopaminergic neurons
and microglia; this can be prevented by EUK. Dopamine can be oxidized by H2O2 through dopamine quinone formation to stable dopaminochrome
(DACHR). DACHR can extract an electron from the auto-oxidizable site of mitochondrial complex I forming DACR radical and impacting selectively on
complex I function. Due its high affinity for molecular oxygen, DACR radical can pass an electron on to this molecular species resulting in its re-
reduction to DACHR and increased formation of mitochondrial superoxide radical. MAO-B generated H2O2 can also stimulate local microglia;
microglial activation can be greatly secondarily enhanced within the SN due to dopaminergic cell demise which can also exacerbate ROS production
and impact on local dopaminergic neurons.
doi:10.1371/journal.pone.0001616.g009
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synaptosomes
Dopaminergic and non-dopaminergic striatal synaptosomes
were isolated using a modified immuno-magnetic protocol [58].
Briefly, synaptosomes were prepared from dissected striatal tissue
[59]. Dopaminergic synaptosomes were isolated using magnetic
beads conjugated to anti-rabbit IgG (Miltenyi Biotech) after
capturing them using a rabbit anti-DAT antibody (Chemicon).
Under a magnetic field, bead-bound synaptosomes were passed
through a column and washed; flow-through in the presence of the
magnetic field yielded a fraction enriched in non-dopaminergic
striatal synaptosomes. Elution performed in the absence of the
magnetic field yielded fractions enriched in dopaminergic striatal
synaptosomes. Equal quantities of various fractions of the
synaptosomes isolated using DAT antibody including the starting
material or control, the unbound fraction, the flow-through, the
wash and the eluate were subjected to western analysis to assess
relative dopaminergic versus non-dopaminergic synaptosomal
purification. Western blots were performed using antibodies
against TH (Chemicon 1:500), GABA (Chemicon, 1:1000) or
SNAP-25 as a synaptic protein normalization control (Chemicon,
1:1000). Band densities were quantified using a Chemimager
(Alpha Innotech, San Leandro, CA). Approximately 94%
synaptosomes in the eluate were dopaminergic according to
densitometric evaluation of the western blot.
H2O2 estimation in synaptosomes
Hydrogen peroxide levels were measured in the striatal
dopaminergic and non-dopaminergic synaptosomes prepared as
above from various groups of mice. Mice were injected in the tail
vein with ,200 ml of DCFDA (Calbiochem) which was freshly
diluted 100 x with PBS from a stock of 100 mg/ml in DMSO as
modified from Andrews et. al. [38]. The animals were sacrificed
3 hours later and synaptosomes were prepared as above.
Hydrogen peroxide in the synaptosomes with or without 1mg/
ml catalase for 30 min after preparation was visualized as DCF
fluorescence at 488 nm excitation and 512 nm emission in a
Spectramax Gemini fluorescence plate reader. The relative
fluorescence was normalized to synaptosomal protein which was
quantified using the Bradford reagent, Bio-Rad.
Mitochondrial complex I and IV activities
Isolated synaptosomes were found to be physiologically viable
for up to 3 hours. Complex I activities were assayed in isolated
dopaminergic and non-dopaminergic synaptosomal fractions from
dox-induced animals as rotenone-sensitive NADH dehydrogenase
activity by measuring DCPIP (2,6-dichlorophenolindophenol)
reduction in synaptosomal extracts following addition of 200 mM
NADH, 200 mM decylubiquinone, 2 mM KCN, and 0.002%
DCPIP in the presence and absence of 2 mM rotenone [60].
Complex IV activity was assayed as cytochrome c oxidase activity
by observing the rapid (1–2s) oxidation of freshly reduced 40 mM
ferrocytochrome c in a 10 mM K-PO4 buffer pH 7.2 containing
100 mM KCl, 0.025% maltoside at 30uC, at 550 nm, averaged
over two concentrations per sample. Values for all assays were
normalized/protein using BioRad reagent.
Detection of mitochondrial superoxide in vivo
Mitosox Red (Molecular Probes) was used as an indicator to
assess presence of superoxide within cellular mitochondria. 10 mg
of Mitosox in 200 ml phosphate-buffered saline was injected into
the tail vein of dox-induced transgenics versus controls. Animals
were sacrificed 90 minutes later, brains rapidly dissected out and
post-fixed overnight in 4% paraformaldehyde. Brains were
sectioned at 30 mm using a cryostat. Cellular localization and site
of Mitosox Red accumulation in the nigrostriatum was identified
by immunofluorescence using anti-TH (Chemicon, 1:500), anti-
IBA1 (Wako, 1:500) or anti-GFAP (DAKO, 1:500) antibodies
visualized with Fluorescein Avidin D. Mitochondrial localization
was confirmed by immunoanalysis using an anti-ATP synthase-
specific antibody. Fluorescent imaging was done using a Zeiss
LSM510 NLO confocal microscope and images procured using
LSM software. Quantification of colocalization and fluorescent
intensity was determined using the IMARIS software suite
(Bitplane AG, Zurich, Switzerland) on selected cells from multiple
sections.
Morphological analyses of astrocyte and microglial
activation
Immunochemistry was performed on cryosections derived from
the SN, striata, and CTX of fixed perfused brains from dox-
induced transgenics versus controls. Astrocytic activation was
assessed using primary antibodies against GFAP and s100-b.
Microglial activation was detected using primary antibodies
against Iba1. Horse radish peroxidase or avidin-conjugated
secondary antibodies were used to detect primary antibodies
following either DAB or Fluorescein/Texas Red staining.
Locomotor behavioral assessment
Locomotor function was assessed using an automated Truscan
photobeam apparatus (Colbourne Instruments, Allentown, PA)
under illumination as previously described [61]. Animals were
habituated to the apparatus for 10 min then data collected over a
10-min period followed by analysis using Truscan 99 software.
Spontaneous horizontal movement was assessed in both control
and dox treated versus untreated transgenic mice via both
ambulatory velocity and distance in a 10-min period.
Supporting Information
Figure S1 Microglial activation is largely absent in the cortex.
Absence of detectable microglial activation in the cortical sections
from untreated, dox-treated deprenyl co-treated animals. Iba1
immunocytochemistry reveals that cortical microglia are in a
resting ramified stage in all the three types of treatments conditions
in contrast to what occurs in the striatum and the substantia nigra
(Figure 6). This suggests that activation in the nigrostriatum may
largely be due to secondary effects as a consequence of SN
dopaminergic demise. Two representative micrographs are
provided from each treatment.
Found at: doi:10.1371/journal.pone.0001616.s001 (10.35 MB
TIF)
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